JMJD6

Across TCGA pan-cancer cohorts, JMJD6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated JMJD6 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher JMJD6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated JMJD6 expression acts as an unfavorable survival marker.

READ, ESCA, and UCEC are the cancer types where JMJD6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.082	0.845	<.001	18	view →
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	All	0.176	0.835	<.001	6	view →
STAD	OS	Median	III,IV	0.500	0.633	.010	5	view →
COAD	DFS	Median	II,III,IV	0.223	0.648	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

JMJD6–READ (DFS)

Open the READ breakdown →